FDA-cleared profile

BunkerHill BMD

BunkerHill Health · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Analyzes existing CT images in DICOM format from adults aged 30 years and older to estimate average areal BMD of spinal bones and flag low bone density below a preset threshold, including opportunistic scans without a phantom; it does not replace DXA or other dedicated BMD testing.

Clinical role
Post-processes existing CT scans to estimate DXA-measured average areal bone mineral density of spinal bones and flag low bone density below a pre-specified threshold, as information assisting clinicians; not a replacement for DXA or primary decision input.
Images and patients
CT/CTA · Spine
Key limitation
Keep in mind: The output is a finding of interest and not a primary decision input; it does not replace DXA or dedicated BMD testing, and existing CT quality, DICOM routing, and local report integration require site validation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Analyzes existing CT images in DICOM format from adults aged 30 years and older to estimate average areal BMD of spinal bones and flag low bone density below a preset threshold, including opportunistic scans without a phantom; it does not replace DXA or other dedicated BMD testing.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Spine Input: Existing CT scans of adults 30 years and above, sent to the software in DICOM format and analyzed for spinal bone mineral density, including CT scans acquired for other purposes.
  • Who uses it?Intended users: Healthcare provider
  • What does the software produce?Output: The device outputs an estimated DXA-measured average areal bone mineral density of spinal bones, a flag for low bone density below a pre-specified threshold, a calibrated BMD score, and a T-score group. Results can be copied to clipboard, inserted in report, or output as DICOM Secondary Capture.
  • What is its most important limitation?Key limitation: The output is a finding of interest and not a primary decision input; it does not replace DXA or dedicated BMD testing, and existing CT quality, DICOM routing, and local report integration require site validation.

Clinical takeaway. Clinical role: Analyzes existing CT images in DICOM format from adults aged 30 years and older to estimate average areal BMD of spinal bones and flag low bone density below a preset threshold, including opportunistic scans without a phantom; it does not replace DXA or other dedicated BMD testing.

Evidence takeaway. Evidence from the reviewed source record: Study type: Stand-Alone Performance. Cases: 371. Sites: 4. Reported sensitivity: 81% (95% CI: 74%, 86.8%). Reported specificity: 78.4% (95% CI: 72.3%, 83.7%)

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Analyzes existing CT images in DICOM format from adults aged 30 years and older to estimate average areal BMD of spinal bones and flag low bone density below a preset threshold, including opportunistic scans without a phantom; it does not replace DXA or other dedicated BMD testing.
  • Exact FDA submission
  • Checked 2026-09-06

Exact clinical-use normalization from the FDA packet; this text is also the locked corrections value.

Workflow role
Post-processes existing CT scans to estimate DXA-measured average areal bone mineral density of spinal bones and flag low bone density below a pre-specified threshold, as information assisting clinicians; not a replacement for DXA or primary decision input.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The Bunkerhill BMD Algorithm is a post-processing AI-powered software intended for adults 30 years and above to assess estimated DXA-measured average areal bone mineral density of spinal bones from existing CT scans and outputs a flag for low bone density below a pre- specified threshold." … "It is not intended to replace DXA or any other tests dedicated to BMD measurement.". Read from the exact FDA decision document on 2026-11-14.

Required input
Existing CT scans of adults 30 years and above, sent to the software in DICOM format and analyzed for spinal bone mineral density, including CT scans acquired for other purposes.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The Bunkerhill BMD Algorithm is a post-processing AI-powered software intended for adults 30 years and above to assess estimated DXA-measured average areal bone mineral density of spinal bones from existing CT scans" … "Both devices analyze computed tomography (CT) images that are sent to the software in DICOM format.". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
The device outputs an estimated DXA-measured average areal bone mineral density of spinal bones, a flag for low bone density below a pre-specified threshold, a calibrated BMD score, and a T-score group. Results can be copied to clipboard, inserted in report, or output as DICOM Secondary Capture.
  • Exact FDA submission
  • Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Healthcare provider
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
The output is a finding of interest and not a primary decision input; it does not replace DXA or dedicated BMD testing, and existing CT quality, DICOM routing, and local report integration require site validation.
  • Exact FDA submission
  • Checked 2026-09-06

Exact-product limitations and clinician-review boundary from the FDA packet.

Evidence summary
Study type: Stand-Alone Performance. Cases: 371. Sites: 4. Reported sensitivity: 81% (95% CI: 74%, 86.8%). Reported specificity: 78.4% (95% CI: 72.3%, 83.7%)
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Study type: Stand-Alone Performance. Cases: 371. Sites: 4. Reported sensitivity: 81% (95% CI: 74%, 86.8%). Reported specificity: 78.4% (95% CI: 72.3%, 83.7%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
81% (95% CI: 74%, 86.8%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
78.4% (95% CI: 72.3%, 83.7%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Sensitivity

81 percent

  • EndpointLow-bone-density flag sensitivity against the regulatory reference
  • Population371 CT studies from 4 geographically diverse sites
  • Tested versionBunkerHill BMD; FDA submission K242295

Specificity

78.4 percent

  • EndpointLow-bone-density flag specificity against the regulatory reference
  • Population371 CT studies from 4 geographically diverse sites
  • Tested versionBunkerHill BMD; FDA submission K242295

BunkerHill BMD regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K242295
  • Samplen=371
  • Sites4
  • IndependenceIndependence not established

K242295

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Existing CT scans of adults 30 years and above, sent to the software in DICOM format and analyzed for spinal bone mineral density, including CT scans acquired for other purposes.

    Scope: Exact FDA submission. Packet wording: "The Bunkerhill BMD Algorithm is a post-processing AI-powered software intended for adults 30 years and above to assess estimated DXA-measured average areal bone mineral density of spinal bones from existing CT scans" … "Both devices analyze computed tomography (CT) images that are sent to the software in DICOM format.". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · FDA 510(k) decision material K242295: BunkerHill BMD

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · BunkerHill BMD model card (K242295)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-10-27 ·

  4. Returned objects

    Source context, not route validation: The device outputs an estimated DXA-measured average areal bone mineral density of spinal bones, a flag for low bone density below a pre-specified threshold, a calibrated BMD score, and a T-score group. Results can be copied to clipboard, inserted in report, or output as DICOM Secondary Capture.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-01 · BunkerHill BMD model card (K242295)

  5. Viewer/worklist/report

    Unresolved route: The device outputs an estimated DXA-measured average areal bone mineral density of spinal bones, a flag for low bone density below a pre-specified threshold, a calibrated BMD score, and a T-score group. Results can be copied to clipboard, inserted in report, or output as DICOM Secondary Capture.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-01 · BunkerHill BMD model card (K242295)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Security
Bunkerhill Health's website states SOC 2 Type II certification, HIPAA compliance and ISO/IEC 27001:2022 certification. Badges only: no scope, dates or controls are given. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Existing-CT opportunistic workflow

The official Bunkerhill BMD page describes use of existing non-contrast abdominal CT without additional imaging hardware, a calibration phantom, or additional radiation.

product family · checked 2026-09-06

Exact FDA labeling controls supported CT inputs and patient criteria.

Family Carebricks navigation

The official page describes integration within the Bunkerhill Carebricks platform to support follow-up care navigation after a low-density flag.

product family · checked 2026-09-06

Family-platform statement; interface and local implementation terms require confirmation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242295
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Imaging modality reported in the exact-submission ACR AI Central model card.

Anatomy
Spine
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Anatomy normalized from explicit exact-submission ACR model-card wording.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-08
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored exact-submission candidate metadata had zero PubMed and ClinicalTrials.gov identifiers; this metadata screening is not a full paper or registry-record review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact FDA submission

    Official non-FDA product sources were reviewed for buyer and workflow context, but no exact-submission amount, currency, unit, term, or implementation fee was displayed. A vendor quote remains required.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Bunkerhill BMD reimbursement CPT CMS"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. The Bunkerhill clearance page was read and states no coding or payment; CMS bone mass measurement policies surfaced as general results and are not bound to this product. This records what was found, not that none exists.

  • Deployment: Not verified - checked 2026-10-27 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-08-13 - Exact FDA submission

    Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

  • Monitoring: Not verified - checked 2026-08-13 - Exact FDA submission

    Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

9 sources - 3 history items

Source ledger

  1. K242295 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BunkerHill BMD model card (K242295)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision material K242295: BunkerHill BMD

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinical, evidence, implementation

  8. Bunkerhill BMD FDA clearance

    Bunkerhill Health - Accessed 2026-09-06

    Scope: buyer_workflow, clinical, implementation

  9. Bunkerhill Health home page security claims

    Bunkerhill Health - Accessed 2026-10-25

    Scope: security

Research history

  1. K242295 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K223424

Spine Auto Views

GE Medical Systems SCS

Authorized purpose: Use with CT images to automatically generate anatomically focused multi-planar spine reformats, apply vertebral-body and intervertebral-disc labels, and export the results to predetermined DICOM destinations for review.

Modality
CT/CTA
Anatomy
Spine
Decision
2023-07-13
FDA-cleared K222361

AI-Rad Companion (Musculoskeletal)

Siemens Medical Solutions USA, Inc.

AI-Rad Companion (Musculoskeletal) is an image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of musculoskeletal disease. It provides the following functionality: • Segmentation of vertebras • Labelling of vertebras • Measurements of heights in each vertebra and indication if they are critically different • Measurement of mean Hounsfield value in volume of interest within vertebra. Only DICOM images of adult patients are considered to be valid input.

Modality
CT/CTA
Anatomy
Spine
Decision
2022-10-20
FDA-cleared K193267

Al-Rad Companion (Musculoskeletal)

Siemens Medical Solutions USA, Inc.

Authorized purpose: Provides quantitative and qualitative analysis of previously acquired CT DICOM images to support radiologists and physicians in musculoskeletal-disease assessment.

Modality
CT/CTA
Anatomy
Spine
Decision
2020-03-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history